We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Microneedle Skin Patch Detects Melanoma Without Biopsy or Blood Draw

By LabMedica International staff writers
Posted on 28 Jul 2025

Melanoma, the most aggressive form of skin cancer, currently requires patients, especially those with fair skin and moles, to undergo regular doctor visits and biopsies every six months to determine if growths are malignant or benign. More...

This process can be invasive, costly, and time-consuming. Traditional diagnostic methods often involve blood draws or surgical biopsies, making them inaccessible for routine, rapid screening. Detecting melanoma early is crucial to improving outcomes, but limitations in current testing options delay diagnosis and increase patient anxiety. Now, researchers have developed a skin patch and test strip that allow for non-invasive, rapid detection of melanoma without the need for a biopsy or blood sample.

ExoPatch, developed by researchers at the University of Michigan (Ann Arbor, MI, USA), is a silicone patch embedded with star-shaped microneedles that are just 0.6 mm long. These microneedles are coated with a gel containing Annexin V protein that attracts and captures exosomes, tiny vesicles released by cells from interstitial fluid in the epidermis. Once applied to the skin, the microneedles painlessly penetrate only the topmost layer without drawing blood. After 15 minutes, the patch is removed and placed in acid, dissolving the gel and releasing the exosomes into a solution. A test strip, similar to an at-home COVID-19 test, is then dipped into the solution: two lines indicate the presence of melanoma exosomes, while one line indicates a negative result.

The ExoPatch was first validated on pig skin samples due to their similarity to human skin, with microscopy confirming microneedle penetration of 350 to 600 nanometers well within the epidermis. The system was then tested on tissue samples from mice, half of which had been injected with human melanoma tumor fragments. The patch successfully adhered to exosomes in the 30 to 150 nanometer range and was able to distinguish between melanoma and healthy tissue with a 3.5-fold darker test line for melanoma samples. The findings, published in Biosensors and Bioelectronics, showed that the patch isolated 11.5 times more exosomal protein from melanoma tissues, indicating high specificity. Future plans include a pilot study in humans followed by clinical trials. The gel coating of the ExoPatch could also be modified to detect exosomes from other solid tumors such as lung, breast, colon, prostate, and brain cancers.

“This is the first patch designed to capture disease-specific exosomes from fluid under the skin. The potential applications are huge,” said Sunitha Nagrath, co-corresponding author of the study.

Related Links:
University of Michigan


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Platelet Function Analyzer
PL-12
Urine Analyzer
respons® UDS100
New
Slide Scanner System
NanoZoomer S540MD
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers from the Department of Chemistry at Aarhus University have developed and tested a new technology that can identify and measure the concentration of pharmaceuticals in under 10 minutes. Today, this process takes up to an hour. That is critical waiting time for patients suffering from a stroke. (Image Credit: Aarhus University)

Point-of-Care Blood Test Could Speed Treatment Decisions in Acute Stroke

Minutes can shape treatment decisions in emergency stroke care, particularly when physicians need to know whether a patient is taking anticoagulants before administering clot-dissolving therapy.... Read more

Microbiology

view channel
Image: The clearance also broadens QIAstat-Dx\'s infectious disease testing menu in the U.S., which already includes panels for respiratory and gastrointestinal infections, as well as meningitis and encephalitis (Photo courtesy of Qiagen)

One-Hour Molecular Panel Expands Bloodstream Infection Testing for Gram-Negative Pathogens

Bloodstream infections can progress rapidly and lead to sepsis, organ failure, and death. In the United States, about 1.7 million adults develop sepsis each year, and at least 350,000 die during hospitalization... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.